Table 2.

Spinal Neurofibroma (SNF) Assessment After Completing 12 Cycles of Selumetinib Treatment

Evaluation of the Effect of Seluemtinib on SNFs After 12 Cycles of Selumetinib
Evaluable Patients (N = 23)	Baseline	Cycle 12
Spinal canal distortion (N)	Present: 23	Resolved: 1
	Absent: 0	Improved: 17
		No change: 5
		Worsened: 0
Disruption of circumferential CSF (N)	Present: 19	Resolved: 4
	Absent: 4	Improved: 13
		No change: 2
		Worsened: 0
Spinal cord deformity (N)	Present: 19	Resolved: 1
	Absent: 1	Improved: 9
	Not applicable: 3	No change: 9
		Worsened: 0